Hong Jiang, Ph.D.
Department of Neuro-Oncology, Division of Cancer Medicine
About Dr. Hong Jiang
My research interest has been focused on developing oncolytic adenoviral therapy for solid cancers. Meanwhile, I have been engaged in basic virology and cancer biology studies. I am the first to report oncolytic adenovirus induces autophagy in glioma cells and describe autophagy as part of the mechanism for the virus to lyse host cell (J Natl Cancer Inst 2007, J Virol 2011). My work has contributed to the first Phase I clinical trial of oncolytic adenovirus Delta-24-RGD in glioma patients with poor prognosis. To improve the potency of Delta-24-RGD, I developed Delta-24-RGDOX which expresses immune co-stimulator OX40 ligand to enhance the virus-mediated anti-tumor immunity (Cancer Res 2017). Moreover, combination of this virus with intratumoral injections of anti-PD-L1 antibody synergized to reject gliomas. In addition, I investigated the systemic anti-cancer effect of this virus in melanoma mouse models with disseminated/metastatic tumors (Clin Cancer Res. 2019). The work revealed that localized viral injection to the subcutaneous tumor induced abscopal anti-tumor effect on untreated disseminated tumors, including intracranial tumors. A human version of Delta-24-RGDOX has been tested clinically in patients with recurrent glioblastoma (NCT03714334) and resectable colorectal liver metastasis (NCT04714983). My work of immunological study on oncolytic adenovirus Delta-24 platform has initiated further studies on this topic from my collaborators. Currently, my work is focused on examining the effect of combining oncolytic adenoviruses with adoptive T cell therapy, including CAR T cell therapy, in glioma and melanoma models in immunocompetent mice (Cancer Res Commun 2023).
Present Title & Affiliation
Primary Appointment
Associate Professor, Neuro-Oncology - Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Neuro-Oncology - Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Research Interests
Currently, my work is exploring the oncolytic adenovirus-mediated anti-tumor immunity through constructing novel oncolytic adenoviruses expressing immune stimulators and combining them with CAR T cell therapy. My long-term goal is to develop more efficacious and safer therapeutic regimens that can be tested in patients with advanced metastatic solid tumors that are refractory to other conventional therapies.
Education & Training
Degree-Granting Education
| 1997 | Beijing Normal University, Beijing, CN, Cell and Molecular Biology, Ph.D |
| 1990 | Wuhan University, Wuhan, CN, Molecular Biology, BS |
Postgraduate Training
| 1997-2001 | Post-Doctoral Fellowship, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Neuro-Oncology - Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2008 - 2016
Instructor, Neuro-Oncology - Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2003 - 2008
Research Associate, Neuro-Oncology - Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2001 - 2003
Other Professional Positions
Faculty Senator, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - 2027
Editorial Activities
Member of Editorial Review Board, Biology, 2023 - Present
Associate Editor, American Journal of Cancer Research, 2010 - Present
Honors & Awards
| 1997 | Excellent Thesis Award, Beijing Normal University, Beijing, China |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2019. Viroimmunotherapy for gliomas and brain metastases. Invited. The glioblastoma moon shot monthly seminar series presents. Houston, Texas, US.
- 2010. Adenovirus Mediated Autophagy & Cancer. Conference. University of Texas. Houston, TX, US.
- 2006. E1A and E1A mutant adenoviruses in glioma therapy. Conference. UTMDACC. Houston, TX, US.
- 2005. Untargeted Buggin: (Re)engineering Delta-24 advances in oncology. Conference. UTMDACC. Houston, TX, US.
International Presentations
- 2024. Anti-tumor activity of a new oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL-15. Invited. 29th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology. Houston, US.
- 2018. Oncolytic Adenoviruses: The Effect Beyond Oncolysis. Invited. the 2nd International Conference on Genomic Medicine. Houston, US.
- 2010. RB-E2F1: Gatekeepers of Autophagy and Apoptosis. Invited. 15th Annual Scientific Meeting & Education Day of the Society for Neuro-Oncology. Montreal, CA.
- 2009. Erradication of Brain Tumor Stem Cells through Oncolytic Adenovirus-mediated Autophagy. Invited. The 2nd World Cancer Congress. Beijing, CN.
Grant & Contract Support
| Date: | 2025 - Present |
| Title: | The effect of oncolytic adenovirus Delta-24-RGDOX-IL15 on CAR T therapy for gliomas |
| Funding Source: | Uncle Kory Foundation |
| Role: | PI |
| ID: | FP00024278 |
| Date: | 2025 |
| Title: | Medical Scientist Training Program |
| Funding Source: | NIH/NIGMS |
| Role: | TBD |
| Date: | 2025 - Present |
| Title: | Management of metastatic intracranial tumors through extracranial treatment with CAR T cells and oncolytic adenoviruses |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | PI |
| ID: | FP00023213 |
| Date: | 2024 - Present |
| Title: | Combining CAR T cell therapy and oncolytic adenoviral immunotherapy to treat disseminated extracranial and intracranial tumors |
| Funding Source: | NIH |
| Role: | PI |
| ID: | FP00021924 |
| Date: | 2024 - Present |
| Title: | The effect of immune activation mediated by localized treatment of the extracranial tumor with oncolytic adenoviruses on CAR T cells and their trafficking to the brain tumor |
| Funding Source: | Andrew M. McDougall Brain Metastasis Clinic and Research Program |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Anti-glioma activity of oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL-15 |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2024 - 2024 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Cancer NeuroSciences Program |
| Role: | TBD |
| Date: | 2023 - 2024 |
| Title: | Examination of novel protein sensors of oncolytic adenoviruses: implications for therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| Date: | 2023 - 2025 |
| Title: | Examining the Role of Nono Pathway on the Innate Immunity Against Oncolytic Adenoviruses |
| Funding Source: | NIH/NCI |
| Role: | TBD |
| Date: | 2023 - 2025 |
| Title: | Evaluate Intratumoral CAR T Cell Therapy and its Combination with Oncolytic Adenovirus Delta-24-RGDOX in Immunocompetent Mice with Disseminated Tumors |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | FP00017030 |
| Date: | 2023 - 2026 |
| Title: | Redirecting the Immune Response During Oncolytic Virotherapy |
| Funding Source: | Alliance for Cancer Gene Therapy |
| Role: | TBD |
| Date: | 2023 - 2024 |
| Title: | The Cure Starts Now |
| Funding Source: | NIH/NCI |
| Role: | TBD |
| Date: | 2022 - 2023 |
| Title: | Combining oncolytic adenovirus Delta-24-RGDOX and CAR T cells to treat disseminated solid tumors in immunocompetent syngeneic mouse models |
| Funding Source: | The Elsa U. Pardee Foundation |
| Role: | PI |
| ID: | FP00016479 |
| Date: | 2022 - 2023 |
| Title: | Developmental Research Project in the Brain Tumor SPORE: Intramural treatment with CAR T cell therapy and its combination with oncolytic adenovirus Delta-24-RGDOX in immunocompetent mice with malignant glioma |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | P50-CA127001 |
| Date: | 2022 - 2027 |
| Title: | Viroimmunotherapy for Brain Metastases of Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2021 - 2025 |
| Title: | Glioma Therapy with Oncolytic Adenoviruses and Immunometabolic Adjuvants |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA256006 |
| Date: | 2021 - 2022 |
| Title: | Developmental Research Project in the Brain Tumor SPORE: Application of invariant nature killer T cells in oncolytic adenovirotherapy for gliomas |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Combining oncolytic adenoviruses and CAR T cells to treat disseminated melanomas |
| Funding Source: | Melanoma Research Alliance |
| Role: | PI |
| ID: | FP00012481 |
| Date: | 2020 - 2021 |
| Title: | Developmental Research Project in the Brain Tumor SPORE: Role of Invariant Nature killer T cells during Oncolytic Adenovirotherapy for Gliomas |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | P50-CA127001 |
| Date: | 2020 - Present |
| Title: | Combining oncolytic adenoviruses and CAR T cells to treat disseminated solid tumors |
| Funding Source: | Emerson Collective |
| Role: | Principal Investigator-MDACC |
| ID: | FP00009770 |
| Date: | 2020 - 2022 |
| Title: | Systemic anti-tumor immunity induced by combining oncolytic adenoviruses and adoptive T cell therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | Brain Cancer SPORE; Project 1: Tropism Enhanced Oncolytic Adenovirus for Brain Tumor Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2 P50 CA127001 |
| Date: | 2019 - 2020 |
| Title: | Developmental Research Project in the Brain Tumor SPORE: Combining adoptive T cell therapies and oncolytic adenoviruses in glioma therapy |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | P50-CA127001 |
| Date: | 2017 - 2019 |
| Title: | Oncolytic Immunotherapy for gliomas and cancer metastases in the era of checkpoint regulation |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP170066 (ETRA) |
| Date: | 2015 - 2017 |
| Title: | NO TITLE PROVIDED |
| Funding Source: | DNATrix |
| Role: | Key Personnel |
| ID: | Glioma Therapy |
| Date: | 2014 - 2016 |
| Title: | Anti-tumor immunity induced by oncolytic adenovirus |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| Date: | 2014 - 2021 |
| Title: | MoonShoot Brain Tumors |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| Date: | 2014 - 2015 |
| Title: | Developmental Research Project in the Brain Tumor SPORE: Delta-24-RGDOX: enhancement of specific anti-tumor immunity |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50-CA127001 |
| Date: | 2011 - 2013 |
| Title: | Career development program in the Brain Tumor SPORE: Role of autophagy in oncolytic adenovirus-mediated immune response during glioma virotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50-CA127001-01A1 |
| Date: | 2008 - 2013 |
| Title: | Developmental Project in the Brain Tumor SPORE Application; Project 1: Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain Tumors |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50-CA127001-01A1 |
| Date: | 2002 - 2004 |
| Title: | Retargeting the oncolytic adenovirus Delta-24 to malignant glioma cells through a genetically modified chimeric fiber bearing a ligand against EGFRvIII |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Title: | Development of oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL-15 to potentiate CAR T cell therapy for gliomas |
| Funding Source: | Lindonlight Collective |
| Role: | PI |
| ID: | FP00023920 |
| Title: | Oncolytic Adenoviruses and Autophagy Cell Death in Glioma Therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01-CA1411290 |
Selected Publications
Peer-Reviewed Articles
- Shin DH, Jiang H, Gillard AG, Kim D, Fan X, Singh SK, Nguyen TT, Sohoni SS, Lopez-Rivas AR, Parthasarathy A, Ene CI, Gumin J, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther 32(3):722-733, 2024. e-Pub 2024. PMID: 38311852.
- Jiang H, Shin DH, Yi Y, Fan X, Gumin J, He J, Gillard AG, Lang FF, Gomez-Manzano C, Fueyo J. Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity. Cancer Res Commun 3(6):1118-1131, 2023. e-Pub 2023. PMID: 37379361.
- Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Godoy-Vitorino F, Zhu L, Zheng WJ, Zhai L, Ladomersky E, Lauing KL, Alonso MM, Wainwright DA, Gomez-Manzano C, Fueyo J. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer 10(7), 2022. e-Pub 2022. PMID: 35902132.
- Puigdelloses M, Garcia-Moure M, Labiano S, Laspidea V, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, De la Nava D, Ausejo I, Hervás-Stubbs S, Herrador G, Chen Z, Hambardzumyan D, Patino Garcia A, Jiang H, Gomez-Manzano C, Fueyo J, Gállego Pérez-Larraya J, Alonso M. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34281988.
- Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res 25(22):6801-6814, 2019. e-Pub 2019. PMID: 31455679.
- Rivera-Molina Y, Jiang H, Fueyo J, Nguyen T, Shin DH, Youssef G, Fan X, Gumin J, Alonso MM, Phadnis S, Lang FF, Gomez-Manzano C. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv 1(1):vdz009, 2019. e-Pub 2019. PMID: 31608328.
- Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacaín M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solís S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun 10(1):2235, 2019. e-Pub 2019. PMID: 31138805.
- Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77(14):3894-3907, 2017. e-Pub 2017. PMID: 28566332.
- Klein SR, Jiang H, Hossain MB, Fan X, Gumin J, Dong A, Alonso MM, Gomez-Manzano C, Fueyo J. Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens. PLoS One 11(4):e0153814, 2016. e-Pub 2016. PMID: 27093696.
- Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407, 2014. e-Pub 2014. PMID: 24827739.
- Jiang H, White EJ, Ríos-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 85(10):4720-9, 2011. e-Pub 2011. PMID: 21367888.
- Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 Pathway Regulates Autophagy. Cancer Res 70(20):7882-93, 2010. e-Pub 2010. PMID: 20807803.
- Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3):256-65, 2008. e-Pub 2008. PMID: 18927600.
- Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16(3):487-493, 2008. e-Pub 2008. PMID: 18253154.
- Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J. ICOVIR-5 shows E2F1-addiction and potent anti-glioma effect in vivo. Cancer Res 67(17):8255-8263, 2007. e-Pub 2007. PMID: 17804740.
- Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410-4, 2007. e-Pub 2007. PMID: 17848677.
- Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67(9):4005-4007, 2007. e-Pub 2007. PMID: 17483310.
- Lee OK, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, Jiang H, Piao Y, Liu TJ, Gomez-Manzano C. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating NIF-1a levels in gliomas. Oncogene 27(9):1310-1314, 2007. e-Pub 2007. PMID: 17704802.
- Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WKA, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-761, 2007. e-Pub 2007. PMID: 17557108.
- Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, Alonso MM, Gomez-Manzano C, Hung MC, Yung WK, Fueyo J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. Faseb J 20:2603-5, 2006. e-Pub 2006. PMID: 17065226.
- Guo W, Zhu H, Zhang L, Davis J, Teraishi F, Roth JA, Stephens C, Fueyo J, Jiang H, Conrad C, Fang B. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 13(1):82-90, 2006. e-Pub 2006. PMID: 16037823.
- Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556-62, 2006. e-Pub 2006. PMID: 16428500.
- Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 97(21):1589-600, 2005. e-Pub 2005. PMID: 16264179.
- Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7(8):723-9, 2005. e-Pub 2005. PMID: 16207474.
- Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. e-Pub 2005. PMID: 15720816.
- Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine MG, Fueyo J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 11(11):713-20, 2004. e-Pub 2004. PMID: 15332115.
- Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10):1821-8, 2004. e-Pub 2004. PMID: 15014451.
- Yang LY, Jiang H, Rangel KM, Plunkett W. Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01). Oncol Rep 10(5):1489-95, 2003. e-Pub 2003. PMID: 12883729.
- Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60, 2003. e-Pub 2003. PMID: 12734316.
- Yang LY, Jiang H, Rangel KM. RNA polymerase II stalled on a DNA template during transcription elongation is ubiquitinated and the ubiquitination facilitates displacement of the elongation complex. Int J Oncol 22(3):683-9, 2003. e-Pub 2003. PMID: 12579324.
- Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1):109-17, 2003. e-Pub 2003. PMID: 12509854.
- Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6(3):773-81, 2000. e-Pub 2000. PMID: 10741696.
- Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res 59(18):4529-34, 1999. e-Pub 1999. PMID: 10493501.
- Jiang H, Feng J, Wang YC. Differential cell cycle regulation between V79 and V79-8 cells. Acta Anatomica Sinica 29(4):387-3896, 1998. e-Pub 1998.
- Jiang H, Feng J, Wang YC. Effect of p21Cip1 gene on the cell cycle regulation of V79-8 cells. Acta Anatomica Sinica 29(3):264-2697, 1998. e-Pub 1998.
- Jiang H, Feng J, Wang YC. P21 Cip1 antisense RNA inhibits the differentiation of HL-60 cells induced by all-trans retinoic acid. Progress in Natural Sciences 8(5):513-5205, 1998. e-Pub 1998.
Invited Articles
- He J, Munir F, Ragoonanan D, Zaky W, Khazal S, Tewari P, Fueyo J, Gomez-Manzano C, Jiang H. Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. Immuno 3(1):37-56, 2023. e-Pub 2023.
- Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. Cancers (Basel) 10(6), 2018. e-Pub 2018.
- Klionsky DJ, Abdelmohsen K, Akihisa A, Jiang H, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. e-Pub 2016. PMID: 26799652.
- Jiang H, Gomez-Manzano C, Rivera-Molina Y, Lang FF, Conrad CA, Fueyo J. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol 13:33-39, 2015. e-Pub 2015. PMID: 25863716.
- Jiang, Fueyo. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy. OncoImmunology 3(7):e947872, 2014. e-Pub 2014. PMID: 25954598.
- Klionsky DJ, Abdalla FC, Abeliovich H, Jiang H, Zschocke J, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. e-Pub 2012. PMID: 22966490.
- Balvers R, Jiang H, Piya S, Gomez-Manzano C, Fueyo J. Adenovirus, Autophagy, and Lysis: Ecstasies and Agonies. Future Virology 6(10):1161-1164, 2011. e-Pub 2011.
- White EJ, Martin V, Liu JL, Klein SR, Piya S, Gomez-Manzano C, Fueyo J, Jiang H. Autophagy Regulation in Cancer Development and Therapy. Am J Cancer Res 1(3):362-372, 2011. e-Pub 2011.
- Jiang H, Martin V, Alonso M, Gomez-Manzano C, Alonso M, Fueyo J. RB-E2F: Molecular rheostat for autophagy and apoptosis. Autophagy 6(8):1216-7, 2010. e-Pub 2010.
- Jiang H, Fueyo J. Eradication of brain tumor stem cells with an oncolytic adenovirus. Discov Med 10(50):24-8, 2010. e-Pub 2010.
- Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr gene Ther 9(5):422-7, 2009. e-Pub 2009.
- Gomez-Manzano C, Alonso M, Jiang H, Fueyo J. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther 11(7):794-6, 2008. e-Pub 2008. PMID: 18756625.
- Klionsky DJ, Abeliovich H, Jiang H, Deter RL. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151-75, 2008. e-Pub 2008. PMID: 18188003.
- Jiang H, White EJ, Gomez-Manzano C, Fueyo J. Adenovirus's last trick: You say lysis, we say autophagy. Autophagy 4(1):118-20, 2008. e-Pub 2008. PMID: 18032923.
- Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 6(5):697-708, 2006. e-Pub 2006. PMID: 16759161.
- Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 6(11):1585-92, 2006. e-Pub 2006. PMID: 17134363.
- Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:577-588, 2003. e-Pub 2003.
- Jiang H, Wang YC. Research progress in cyclin-dependent kinase inhibitor p21Cip1. Progress in Physiological Science 29(4):339-3418, 1998. e-Pub 1998.
- Jiang H, Wang YC. Mechanism of cell cycle regulation. Trends in Cell Biology 2(9):1-16, 1998. e-Pub 1998.
- Jiang H, Wang YC. Cyclin-dependent kinase inhibitors in mammalian cells. Progress in Physiological Science 27(2):107-112, 1996. e-Pub 1996.
Review Articles
- He J, Connors J, Meador A, Xu S, Meador H, Jiang H, Fueyo J, Gomez-Manzano C, Friedman GK, Zaky W, Sadighi Z, Slopis JM, Ahmad AH. Immunotherapy-related neurotoxicity in the central nervous system of children with cancer. Neuro Oncol, 2024. e-Pub 2024. PMID: 39535217.
- Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:d577-88, 2003. e-Pub 2003. PMID: 12700119.
Other Articles
- Gillard A, Shin DH, Jiang H, Fan X, Laspidea V, He J, Lopez-Rivas A, Parthasarathy A, Alonso MM, Lang FF, Fueyo J, Gomez Manzano C New Immunomodulatory roles of NONO pathway during glioma virotherapy. J Immunother Cancer, 2023.
- Gillard A, Dh S, Laspidea V, Singh SK, Jiang H, Kim D, Fan X, Yi Y, Lang F, Alonso M, Fueyo J, Gomez-Manzano C NONO is a new adenovirus sensor: Implication for virotherapy. Neuro Oncol, 2022.
- Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors. J Immunother Cancer, 2022.
Abstracts
- Jiang H, He J, Duran A, Godina Riera CS, Shin DH, Parthasarathy A, Lopez-Rivas AR, Gillard AG, Lang F, Manzano CG, Fueyo J. Oncolytic Adenoviruses Induce Tertiary Lymphoid Structures in Brain Tumors to Promote Durable Antitumor Immunity. https://ror.org/0481e3r23. e-Pub 2026.
- Parthasarathy A, Frost M, Gillard A, Shin DH, Rivas AL, Jiang H, Fan X, Rivera AM, Riera CS, Gomez-Manzano C, Fueyo J. P300/CBP Blockade Boosts Therapeutic Efficacy of Delta-24-RGD Against Diffuse Midline Glioma. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back. e-Pub 2025.
- Jiang H, He J, Duran A, Fan X, Shin DH, Frost M, Parthasarathy A, Lopez-Rivas A, Gillard A, Gumin J, Lang F, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus armed with immune stimulators: a promising partner for CAR T cell therapy in primary and metastatic malignant brain tumors. 2025 WFNOS and SNO Annual Meeting. e-Pub 2025.
- Parthasarathy A, Frost M, He J, Gillard A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Venneti S, Phoenix T, Alonso M, Lang F, Gomez-Manzano C, Fueyo J. Novel therapy for diffuse midline glioma: Targeting oncohistone drivers with P300/CBP inhibition and Delta-24-RGD. 2025 WFNOS and SNO Annual Meeting. e-Pub 2025.
- Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. 2025 WFNOS and SNO Annual Meeting. e-Pub 2025.
- Lopez-Rivas A, Gillard A, Parthasarathy A, Shin DH, Moure MG, Hampton L, He J, Jiang H, Fan X, Wainwright D, Quintana F, Fueyo J, Manzano CG. TARGETING THE AHR IMMUNOMETABOLIC HUB DURING VIROIMMUNOTHERAPY OF GLIOMAS. Neuro Oncol 26(Supplement_8):viii160, 2024. e-Pub 2024.
- Moure MG, Lopez-Rivas AR, Parthasarathy A, Shin DH, Jiang H, He J, Tran HN, Yun K, Hernandez-Osuna R, Alonso MM, Phoenix TN, Wainwright DA, Fueyo J, Oxford University CG©TAPB. CRACKING THE ROLE OF ONCOMETABOLITES IN VIROIMMUNOTHERAPY FOR PEDIATRIC MALIGNANT BRAIN TUMORS. Neuro Oncol 26(Supplement_8):viii163, 2024. e-Pub 2024.
- Gillard A, Shin DH, Laspidea V, Singh S, Jiang H, Xuejun F, Lopez-Rivas A, Parthasarathy A, He J, Garcia-Moure M, Fueyo J. GUARDIANS OF INNATE IMMUNE ACTIVATION: CRUCIAL ROLES OF NONO AND CGAMP IN GLIOMA VIROTHERAPY. Neuro Oncol 26(Supplement_8):viii154, 2024. e-Pub 2024.
- Parthasarathy A, Moure M, He J, Gillard A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Phoenix T, Lang F, Young N, Alonso M, Gomez-Manzano C, Fueyo J. Acetylation Suppression Meet Oncolytic Viruses for the Treatment of Pediatric Diffuse Midline Glioma. Neuro Oncol 26(Supplement_8):viii244, 2024. e-Pub 2024.
- Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang FF, Gomez-Manzano C, Fueyo J. Anti-tumor activity of a new oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL-15. Neuro Oncol 26(Supplement_8):viii249, 2024. e-Pub 2024.
- Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang F, Gomez-Manzano C, Fueyo J. Winning the Tug of War Between Virus and Tumor Immunodominance in Gliomas Treated with Oncolytic Adenoviruses Using Tolerogenic Strategies. Neuro Oncol 26(Supplement_8):viii241, 2024. e-Pub 2024.
- Shin DH, Ozpolat B, Gillard A, Moure MG, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Alatrash G, Lang F, Manzano CG, Fueyo J. Refocusing on tumors: overcoming antiviral immunity in oncolytic virotherapy. 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) November 6-10 | Houston, TX, 2024. e-Pub 2024.
- Lopez-Rivas A, Gillard A, Parthasarathy A, Shin DH, Moure M, Hampton L, He J, Jiang H, Fan X, Wainwright D, Quintana F, Fueyo J, Gomez-Manzano C. Targeting the immunometabolic factor AhR boosts glioma viroimmunotherapy. 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) November 6-10 | Houston, TX, 2024. e-Pub 2024.
- Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang FF, Gomez-Manzano C, Fueyo J. Antitumor activity of CAR T cells potentiated by oncolytic adenoviruses armed with immune stimulators. 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) November 6-10 | Houston, TX, 2024. e-Pub 2024.
- Jiang XR, Rafei H, Basar R, Daher M, Liang Q, Biederstadt I, Zhang P, Xiong D, Kang J, Gumin J, Shanley M, Jones C, Gilbert A, Shaim H, Muniz-Feliciano L, Deyter G, Banerjee P, Moore M, Li Y, Fang D, Acahrya S, Jiang H, Uprety N, Shrestha R. Oncolytic viruses induce sustained anti-tumor cytotoxicity in NK cells. 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) November 6-10 | Houston, TX, 2024. e-Pub 2024.
- Parthasarathy A, Moure MG, He J, Gillard A, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton L, Delaney J, Phoenix TN, Lang F, Young N, Alonso M, Manzano CG, Fueyo J. Viroimmunotherapy combined with acetylation suppression: Advanced therapeutics for pediatric diffuse midline gliomas. 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) November 6-10 | Houston, TX, 2024. e-Pub 2024.
- Gillard A, Shin DH, Laspidea V, Singh S, Hampton L, Jiang H, Fan X, Lopez-Rivas A, Parthasarathy A, He J, Moure MG, Alonso M, Fueyo J, Manzano CG. Unlocking the Therapeutic Potential of Glioma Virotherapy: NONO and cGAMP as Key Regulators of Innate Immune Activation. 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) November 6-10 | Houston, TX, 2024. e-Pub 2024.
- Moure MG, Lopez-Rivas A, Parthasarathy A, Gillard A, Shin DH, Jiang H, He J, Tran HN, Yun K, Hernández-Osuna R, Labiano S, Alonso M, Phoenix TN, Wainwright D, Fueyo J, Manzano CG. Modulating tumor metabolism to overcome mechanisms of resistance to viroimmunotherapy in pediatric brain tumors. 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) November 6-10 | Houston, TX, 2024. e-Pub 2024.
- Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang FF, Gomez-Manzano C, Fueyo J. Antitumor activity of CAR T cells potentiated by oncolytic adenoviruses armed with immune stimulators. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, 2024. e-Pub 2024.
- Parthasarathy A, Moure M, He J, Gillard A, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton L, Phoenix T, Lang FF, Young N, Alonso MM, Gomez-Manzano C, Fueyo J. Acetylation Suppression Meets Oncolytic Viruses for the Treatment of Pediatric Diffuse Midline Glioma. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
- Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang FF, Gomez-Manzano C, Fueyo J. Refocusing on tumors: overcoming antiviral immunity in oncolytic virotherapy. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
- Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang F, Gomez-Manzano C, Fueyo J. Winning the tug of war between virus and tumor immunodominance in gliomas treated with oncolytic adenoviruses using tolerogenic strategies. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
- Parthasarathy A, Moure MG, He J, Gillard A, Paparella A, Shin DH, Lopez-Rivas A, Jiang H, Fan X, Hampton L, Delaney J, Phoenix T, Lang F, Alonso M, Young N, Gomez-Manzano C, Fueyo J. Viroimmunotherapy combined with acetylation suppression: advanced therapeutics for pediatric diffuse midline gliomas. Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting 2024, 2024. e-Pub 2024.
- Jiang H, He J, Duran A, Fan X, Shin DH, Parthasarathy A, Gillard A, Lopez-Rivas A, Moure MG, Lang FF, Gomez-Manzano C, Fueyo J. Anti-tumor activity of a new oncolytic adenovirus Delta-24-RGDOX-IL15 co-expressing OX40L and IL-15. Society of Neuro-Oncology (SNO) 29th Annual Meeting and Education Day 2024, 2024. e-Pub 2024.
- Parthasarathy A, Moure MG, He J, Jiang H, Frost M, Lang F, Alonso M, Gomez-Manzano C, Fueyo J. Targeting P300-mediated acetylation in Delta-24-RGD-treated diffuse midline gliomas. 16th Annual International Oncolytic Virotherapy Conference (IOVC 2024). e-Pub 2024.
- Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso MM, He J, Ene C, Al-Atrash G, Lang FF, Gomez-Manzano C. Nanoparticle-induced virus immune tolerance during oncolytic therapy of gliomas. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2024, 2024. e-Pub 2024.
- Parthasarathy A, Moure MG, He J, Shin DH, Gillard A, Lopez-Rivas A, Hampton L, Fan X, Jiang H, Lang F, Alonso M, Gomez-Manzano C, Fueyo J. Targeting hyperacetylation in pediatric diffuse midline gliomas using oncolytic adenoviruses. 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024), 2024. e-Pub 2024.
- Parthasarathy A, Garcia-Moure M, He J, Shin DH, Gillard AG, Lopez-Rivas A, Hampton LA, Fan X, Jiang H, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. TARGETING HYPERACETYLATION IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS USING ONCOLYTIC ADENOVIRUSES. Neuro Oncol 26(Supplement_4):0, 2024. e-Pub 2024.
- Parthasarathy A, Moure M, He J, Shin DH, Gillard AG, Lopez-Rivas A, Hampton LA, Fan X, Jiang H, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Targeting Hyperacetylation in Pediatric Diffuse Midline Gliomas Using Oncolytic Adenoviruses. 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) June 28-July 2 | Philadelphia, PA, 2024. e-Pub 2024.
- Moure M, Lopez-Rivas A, Parthasarathy A, Gillard AG, Shin DH, Jiang H, He J, Tran HN, Yun K, Hernandez-Osuna R, Labiano S, Phoenix MM, Wainwright DA, Fueyo J, Gomez-Manzano C. Exploring Oncometabolite Pathways in Pediatric Brain Tumors as an Actionable Target to Improve Viroimmunotherapy. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) October 23-25 | Barcelona, Spain, 2024. e-Pub 2024.
- Shin DH, Ozpolat B, Gillard A, Moure M, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alemany R, Alonso M, He J, Ene C, Al-Atrash G, Lang F, Gomez-Manzano C, Fueyo J. Nanoparticle-Induced Virus Immune Tolerance During Oncolytic Therapy of Gliomas. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) October 23-25 | Barcelona, Spain, 2024. e-Pub 2024.
- Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. A Chimeric Oncolytic Adenovirus Circumvents Neutralizing Antibodies Developed by Patients with Recurrent Glioblastoma Treated with Delta-24-RGD. 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) 2023, November 16-19 | Vancouver, Canada, 2023. e-Pub 2023.
- Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. A chimeric oncolytic adenovirus circumvents neutralizing antibodies developed by patients with recurrent glioblastoma treated with Delta-24-RGD. 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) 2023, 2023. e-Pub 2023.
- Gillard A, Shin DH, Jiang H, Fan X, Laspidea V, He J, Lopez-Rivas A, Parthasarathy A, Alonso MM, Lang FF, Fueyo J, Gomez Manzano C. New Immunomodulatory roles of NONO pathway during glioma virotherapy. Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023),, 2023. e-Pub 2023.
- Gillard A, Shin DH, Jiang H, Fan X, Laspidea V, He J, Lopez-Rivas A, Parthasarathy A, Alonso MM, Lang FF, Fueyo J, Gomez-Manzano C. Targeting NONO in glioma viroimmunotherapy. 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), 2023. e-Pub 2023.
- Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, Parthasarathy A, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. Single Versus Multiple Injections of Oncolytic Adenoviruses in a Clinical Trial Suggests Strategies to Improve Cancer Virotherapy Through Immune-Evasion Strategies. CICON23 - 7th International Cancer Immunotherapy Conference: Translating Science into Survival, September 20-23 | Milan, Italy, 2023. e-Pub 2023.
- Gillard A, Shin DH, Laspidea V, Singh S, Jiang H, Fan X, Yi Y, He J, Lopez-Rivas A, Lang FF, Fueyo J, Gomez-Manzano C. Implications for virotherapy: a new adenovirus capsid sensor. American Association for Cancer Research (AACR) Annual Meeting 2023, 2023. e-Pub 2023.
- Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Fan X, Yi Y, Ban K, Alemany R, Alonso M, Lang F, Gomez-Manzano C, Fueyo J. Immune Tolerance for Viral Antigens Facilitates Tumoral Epitope Spreading During Oncolytic Virotherapy. International Conference on Brain Tumor Research and Therapy 2023 (ICBTRT), March 26-29 | Kiawah Island, SC, 2023. e-Pub 2023.
- Gupta S, Laspidea V, Fueyo J, Zaky W, Becher O, Nguyen TT, Shin DH, Jiang H, Sohoni S, Fan X, Yi Y, Gumin J, Lang FF, Gomez-Manzano C, Alonso MM. Armed oncolytic adenovirus as experimental therapy for pediatric malignant gliomas. The American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting 2022, Dec 10-13, 2022 | New Orleans, LA, 2022. e-Pub 2022.
- Nguyen TT, Shin DH, Kim D, Singh SK, Jiang H, Gillard A, Fan X, Yi Y, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. Examination of the tumor microenvironment of gliomas treated with viroimmunotherapy reveals the production of oncometabolites leading to new therapeutic strategies. J Immunother Cancer, 2022. e-Pub 2022.
- Nguyen TN, Shin DH, Kim D, Singh SK, Jiang H, Gillard A, Fan X, Yi Y, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. Examination of the tumor microenvironment of gliomas treated with viroimmunotherapy reveals the production of oncometabolites leading to new therapeutic strategies. Neuro Oncol, 2022. e-Pub 2022.
- Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Localized intratumoral treatment with adoptive T cell therapy followed by oncolytic adenovirus Delta-24-RGDOX induces sustainable regression of disseminated solid tumors through antigen spread. Neuro Oncol, 2022. e-Pub 2022.
- Shin DH, Jiang H, Gillard A, Kim D, Nguyen T, Sohoni S, Fan X, Yi Y, Ban K, Alemany R, Alonso M, Lang F, Gomez-Manzano C, Ozpolat B, Fueyo J. Nanoparticle treatment rebalances immunodominance of anti-virus immunity to enhance anti-tumor immunity during oncolytic adenovirus therapy in solid tumors. Neuro Oncol, 2022. e-Pub 2022.
- Shin DH, Jiang H, Gillard A, Kim D, Nguyen TT, Sohoni S, Fan X, Yi Y, Ban K, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Ozpolat B, Fueyo J. Nanoparticle treatment rebalances immunodominance of anti-virus immunity to enhance anti-tumor immunity during oncolytic adenovirus therapy in solid tumors. J Immunother Cancer, 2022. e-Pub 2022.
- Gillard A, Shin DH, Laspidea V, Singh SK, Jiang H, Kim D, Fan X, Yi Y, Lang FF, Alonso MM, Fueyo J, Gomez-Manzano C. Nono is a new adenovirus sensor: implication for virotherapy. J Immunother Cancer, 2022. e-Pub 2022.
- Gillard A, Dh S, Laspidea V, Singh SK, Jiang H, Kim D, Fan X, Yi Y, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. NONO is a new adenovirus sensor: Implication for virotherapy. Society for Neuro-Oncology (SNO) 27th Annual Meeting & Education Day, 2022. e-Pub 2022.
- Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, 2022. e-Pub 2022.
- Nguyen TN, Shin DH, Kim D, Singh SK, Jiang H, Gillard A, Fan X, Yi Y, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. Examination of the tumor microenvironment of gliomas treated with viroimmunotherapy reveals the production of oncometabolites leading to new therapeutic strategies. Society for Neuro-Oncology (SNO) 27th Annual Meeting & Education Day, 2022. e-Pub 2022.
- Jiang H, Shin DH, Yi Y, Fan X, Gumin J, Gillard A, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Localized intratumoral treatment with adoptive T cell therapy followed by oncolytic adenovirus Delta-24-RGDOX induces sustainable regression of disseminated solid tumors through antigen spread. Society for Neuro-Oncology (SNO) 27th Annual Meeting & Education Day, 2022. e-Pub 2022.
- Shin DH, Jiang H, Gillard A, Kim D, Nguyen T, Sohoni S, Fan X, Yi Y, Ban K, Alemany R, Alonso M, Lang F, Gomez-Manzano C, Ozpolat B, Fueyo J. Nanoparticle treatment rebalances immunodominance of anti-virus immunity to enhance anti-tumor immunity during oncolytic adenovirus therapy in solid tumors. Society for Neuro-Oncology (SNO) 27th Annual Meeting & Education Day, 2022. e-Pub 2022.
- Gillard A, Shin DH, Laspidea V, Singh SK, Jiang H, Kim D, Fan X, Yi Y, Lang FF, Alonso MM, Fueyo J, Gomez-Manzano C. Nono is a new adenovirus sensor: implication for virotherapy. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, 2022. e-Pub 2022.
- Shin DH, Jiang H, Gillard A, Kim D, Nguyen TT, Sohoni S, Fan X, Yi Y, Ban K, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Ozpolat B, Fueyo J. Nanoparticle treatment rebalances immunodominance of anti-virus immunity to enhance anti-tumor immunity during oncolytic adenovirus therapy in solid tumors. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, 2022. e-Pub 2022.
- Nguyen TT, Shin DH, Kim D, Singh SK, Jiang H, Gillard A, Fan X, Yi Y, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. Examination of the tumor microenvironment of gliomas treated with viroimmunotherapy reveals the production of oncometabolites leading to new therapeutic strategies. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, 2022. e-Pub 2022.
- Jiang H, Shin DH, Yi Y, Fan X, Gillard A, Gupta S, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus therapy with adaptive cell therapy enhances systemic anti-tumor immunity. 14th International Oncolytic Virotherapy Conference (IOVC), Oct 23-26, 2022 | Karuizawa, Nagano, Japan, 2022. e-Pub 2022.
- Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Strategies to circumvent the antiviral immunity result in enhanced anti-cancer effect of the oncolytic adenovirus Delta-24-RGD. 14th International Oncolytic Virotherapy Conference (IOVC), Oct 23-26, 2022 | Karuizawa, Nagano, Japan, 2022. e-Pub 2022.
- Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Strategies to circumvent the antiviral immunity result in enhanced anti-cancer effect of the oncolytic adenovirus Delta-24-RGD. 14th International Oncolytic Virotherapy Conference (IOVC). e-Pub 2022.
- Jiang H, Shin DH, Yi Y, Fan X, Gillard A, Gupta S, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus therapy with adaptive cell therapy enhances systemic anti-tumor immunity. 14th International Oncolytic Virotherapy Conference (IOVC). e-Pub 2022.
- Jiang H, Shin DH, Sohoni SS, Nguyen TT, Yi Y, Fan X, Gumin J, Singh SK, Lang FF, Gomez-Manzano C, Fueyo J. Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX. J Immunother Cancer, 2021. e-Pub 2021.
- Jiang H, Shin DH, Sohoni SS, Nguyen TT, Yi Y, Fan X, Gumin J, Singh SK, Lang FF, Gomez-Manzano C, Fueyo J. Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX. Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2021. e-Pub 2021.
- Gomez-Manzano C, Melendez C, Nguyen T, Ossimetha A, Jiang H, Fueyo J, Godoy-Vitorino F. Gut Microbiome changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021. e-Pub 2021.
- Jiang H, Nguyen T, Shin DH, Sohoni S, Gupta S, Yi Y, Fan X, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGDOX collaborates with adoptive T cell therapy to sustain systemic anti-tumor immunity. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021. e-Pub 2021.
- Nguyen T, Shin DH, Jiang H, Wainwright DA, Sohoni S, Gupta S, Ossimetha A, Lang F, Alonso MM, Gomez-Manzano C, Fueyo J. Inhibition of the IDO-Kyn-AhR cascade optimizes virotherapy in glioblastoma and depends on CD4 T-cell activation. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021. e-Pub 2021.
- Sohoni S, Nguyen T, Shin DH, Fan X, Jiang H, Gupta S, Ossimetha A, Yi Y, Bartholomeusz C, Alonso M, Fueyo J, Gomez-Manzano C. Targeting the immunosuppressive microenvironment of metastatic breast cancer with viroimmunotherapy. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021. e-Pub 2021.
- Gupta S, Laspidea V, Fueyo J, Becher O, Nguyen T, Shin DH, Jiang H, Sohoni S, Fan X, Yi Y, Gumin J, Lang F, Gomez-Manzano C, Alonso MM. Armed Oncolytic virus for treatment of pediatric DIPG. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021. e-Pub 2021.
- Shin DH, Nguyen TT, Jiang H, Fan X, Yi Y, Sohoni S, Gupta S, Ossimetha A, Gomez-Manzano C, Fueyo J. Evasion of neutralizing antibodies andenhanced anti-tumor effectsof hexon-modified Delta-24-RGD oncolytic adenovirus. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021. e-Pub 2021.
- Shin DH, Nguyen T, Jiang H, Sohoni S, Gupta S, Ossimetha A, Alonso M, Gomez-Manzano C, Fueyo J. Hexon swapping mitigates anti-viralimmune responseduring brain tumor virotherapy. Neuro-Oncol (25th Annual meeting and Education Day of Society for Neuro-oncology; November 18-22, 2020, Virtual) 22(Suppl_2):ii95, 2020. e-Pub 2020.
- Laspidea V, Puigdelloses M, Martinez-Velez N, Garcia-Moure M, Labiano S, Ausejo I, Patiño-García A, Becher OJ, Jiang H, Gupta S, Fueyo J, Gomez-Manzano C, Alonso MM. Oncolytic adenovirus Delta-24-RGD engineered to express 4-1BBl as a therapeutic approach for DIPG. Neuro-Oncol (25th Annual meeting and Education Day of Society for Neuro-oncology; November 18-22, 2020, Virtual) 22(Suppl_2):ii107, 2020. e-Pub 2020.
- Nguyen T, Shin DH, Jiang H, Wainwright D, Sohoni S, Gupta S, Ossimetha A, Lang F, Alonso MM, Fueyo J, Gomez-Manzano C. Delta-24-RGDOX activation of the IDO-Kyn-AhR cascade in glioblastoma: old targets for a new therapy. Neuro-Oncol (25th Annual meeting and Education Day of Society for Neuro-oncology; November 18-22, 2020, Virtual) 22(Suppl_2):ii97, 2020. e-Pub 2020.
- Jiang H, Shin DH, Nguyen T, Lang FF, Gomez-Manzano C, Fueyo J. Systemic immunity against disseminated subcutaneous and intracranial melanomas induced by oncolytic adenovirus Delta-24- RGDOX. J Immunother Cancer. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, November 7-11, Washington, DC 7(Suppl_1):283, 2019. e-Pub 2019.
- Jiang H, Shin DH, Nguyen T, Alonso MM, Lang F, Gomez-Manzano C, Fueyo J. Treatment with Delta-24-RGDOX of subcutaneous tumors results in abscopal effect eradicating intracranial melanomas. Neuro-Oncol (24rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 20-24, Phoenix, AZ) 21(Suppl_6):vi84, 2019. e-Pub 2019.
- Rivera-Molina Y, Fueyo J, Jiang H, Nguyen T, Shin DH, Youssef G, Fan X, Gumin J, Alonso MM, Phadnis S, Lang F, Gomez-Manzano C. Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator GITRL. Neuro-Oncol (24rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 20-24, Phoenix, AZ) 21(Suppl_6):vi87, 2019. e-Pub 2019.
- Nguyen N, Shin DH, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Combined IDO inhibitor and OX40L-armed-oncolytic-adenovirus therapy improves survival in murine glioblastoma. Proceedings of the AACR: Tumor Immunology and Immunotherapy, Nov. 17-20, 2019, Boston, MA, 2019. e-Pub 2019.
- Shin DH, Jiang H, Nguyen T, Youssef G, Fan X, Yi Y, Gomez-Manzano C, Fueyo J. Glioblastoma disguised: combined therapy using CD19 expressing oncolytic adenovirus and CD19-targeted CAR T-cells. Proceedings of the AACR: Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy, Jul. 19-22, 2019, San Francisco, CA, 2019. e-Pub 2019.
- Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen T, Rivera-Molina Y, Lang FF, Gomez-Manzano C, Fueyo J. Systemic anti-melanoma immunity induced by oncolytic adenovirus Delta-24-RGDOX. Proceedings of the AACR Special Conference: Melanoma: From Biology to Target (January 15-18, 2019; Houston, TX), 2019. e-Pub 2019.
- Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen TT, Rivera-Molina Y, Lang F, Gomez-Manzano C, Fueyo J. Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas. J Immunother Cancer. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, November 7-11, Washington, DC 6(Suppl_1):327-328, 2018. e-Pub 2018.
- Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Henry V, Jiang H, Lang F, Fueyo J, Gomez-Manzano C. Inflammatory reprogramming of gliomas using Delta-24-RGDOX and imnunometabolic adjuvants. Neuro-Oncology (23rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 15-18, New Orleans, LA) 20(Suppl_6):vi90-vi91, 2018. e-Pub 2018.
- Jiang H, Nguyen T, Shin DH, Fan X, Gumin J, Bernatchez C, Lang F, Gomez-Manzano C, Fueyo J. In situ autovaccination mediated by oncolytic adenovirus Delta-24-RGDOX induces efficacious immunity against metastatic melanoma. Neuro-Oncology (23rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 15-18, New Orleans, LA) 20(Suppl_6):vi91, 2018. e-Pub 2018.
- Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Carrillo CC, Henry VK, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Forced expression of OX40L and inhibition of IDO within the glioblastoma tumor microenvironment creates a potent anti-tumor immune response. J Immunother Cancer. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, November 7-11, Washington, DC 6(Suppl_1):190, 2018. e-Pub 2018.
- Puerta Martinez F, Yisel A Rivera Y, Nguyen T, Fan X, Rehnuma S, Hossain MB, Jiang H, Bartholomeusz C, Lang FF, Fueyo J, Gomez-Manzano C. Partial reversion of the tumor immunosuppressed environment by oncolytic adenoviruses armed with positive stimulators of the immune synapis in breast cancer. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Chicago, IL, April 14-18, 2018) 78(Suppl_13), 2018. e-Pub 2018.
- Hossain MB, Shifat R, Rivera-Molina Y, Francisco Puerta Martinez F, Jiang H, Kim DK, Johnson DG, Bedford MT, M-C H, Sulman EP, Lang F, Sawaya R, Fueyo J, Gomez-Manzano C. Histone tyrosine phosphorylation determines glioblastoma cell survival. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Chicago, IL, April 14-18, 2018) 78(Suppl_13), 2018. e-Pub 2018.
- Jiang H, Dong A, Carrillo C, Henry V, Fan X, Rivera-Molina Y, Puerta-Martinez F, Nguyen T, Clise-Dwyer K, Lang F, Gomez-Manzano C, Fueyo J. Efficacious anti-melanoma immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. 32nd Annual Meeting of the Society for Immunotherapy of Cancer (National Harbor, MD; Nov. 8-12, 2017), 2017. e-Pub 2017.
- Hossain M, Shifat R, Rivera-Molina Y, PuertaMartinez F, Jiang H, Kim D, Johnson D, Bedford M, Sulman E, Lang F, Fueyo J, Gomez-Manzano C. TIE2-mediated epigenetic modifications regulate radioresistance of glioblastoma. Neuro-Oncol (22nd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 16-19, San Francisco, CA) 19(Suppl_6):vi96, 2017. e-Pub 2017.
- Rivera-Molina Y, Puerta Martinez F, Nguyen T, Jiang H, Fan X, Shifat R, Hossain MB, Henry VK, Carrillo CC, Gomez-Manzano, Fueyo J. Forced expression of GITRL in cancer cells enhances adenovirus-mediated in situ vaccination. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(Suppl_13):4565, 2017. e-Pub 2017.
- Jiang H, Dong A, Rivera-Molina Y, Clise-Dwyer K, Fan X, Puerta Martinez F, Nguyen T, Henry V, Carrillo C, Gomez-Manzano C, Fueyo J. Cancer-killing viruses combined with tumor-targeting immune checkpoint modulation elicits an in situ vaccination effect and expansion of tumor-specific T cells responsible for efficacious systemic anti-cancer activity. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(Suppl_13):3680, 2017. e-Pub 2017.
- Puerta Martinez F, Rivera Y, Nguyen T, Fan X, Henderson JM, Rehnuma S, Hossain MB, Jiang H, Fueyo J, Gomez Manzano C. Oncolytic adenoviruses expressing OX40L or GITRL immune modulators show antitumor effect on immune-competent mouse breast cancer models. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(Suppl_13):3668, 2017. e-Pub 2017.
- Rivera-Molina Y, Jiang H, Puerta Martinez F, Nguyen T, Fan X, Gomez-Manzano C, Fueyo J. Armed-oncolytic virus Delta-24-GREAT expressing GITRL induces potent anti-glioma effect and specific anti-tumor memory. Tumor Immunology and Immunotherapy, American Association for Cancer Research, Boston, MA, October 20-23, 2016, 2016. e-Pub 2016.
- Puerta F, Rivera-Molina Y, Jiang H, Dong A, Fan X, Gomez-Manzano C, Fueyo J. Targeting gliomas and metastatic cancer with oncolytic adenoviruses expressing T-cell activators. DNA Tumor Virus Meeting, McGill Cancer Research Center, Montreal, Quebec, Canada, July 18-23, 2016, 2016. e-Pub 2016.
- Jiang H, Clise-Dwyer K, Bover L, Lang FF, Gomez-Manzano C, Fueyo J. Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand. J ImmunoTher Cancer. (Society for Immunotherapy of Cancer 30th Annual Meeting, National Harbor, MD; November 4-8, 2015) 3(Suppl_2):337, 2015. e-Pub 2015.
- Jiang H, Gomez-Manzano C, Clise-Dwyre K, Bover L Vence LM, Lang FF, Conrad CA, Toniatti C, Tufaro F, Fueyo J. Delta-24-RGDOX: Expressing OX40L in gliomas using replication competent oncolytic adenoviruses induces anti-tumor effect and antiglioma immune memory. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY (September 16-19, 2015), 2015. e-Pub 2015.
- Jiang H, Clise-Dwyer K, Bover L, Lang FF, Yung WKA, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: an oncolytic adenovirus enhances anti-glioma immunity through expressing the immune checkpoint co-stimulator OX40 ligand. 9th International Conference on Oncolytic Virus Therapeutics; Harvard Medical School, June 13-16, 2015, Boston, MA, 2015. e-Pub 2015.
- Jiang H, Alonso M, Hossain MB, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting OX40/OX40L in brain tumors using oncolytic adenoviruses. Cell Symposia: Cancer, Inflammation, and Immunity; June 14-16, 2015; Sitges, Spain, 2015. e-Pub 2015.
- Klein SR, Jiang H, Gomez-Manzano C, Fueyo J. Role of JNK in the regulation of autophagy in adenovirus-infected cancer cells: clinical implications. 2nd Symposium Autophagy- Across Biology and Medicine; April 24, 2015; Houston, TX, 2015. e-Pub 2015.
- Jiang H, Fan X, Clise-Dwyer K, Bover L, Gumin J, Ruisaard KE, Mukheef FJ, Lang FF, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: making cancer more “visible” to the immune system. Proceedings of the 2015 Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia, PA, 2015. e-Pub 2015.
- Cortes-Santiago N, Hossain M, Gabrusiewick K, Fan X, Jiang H, Shifat R, Alonso MM, Fueyo J, Gomez-Manzano C. Counterattacking the force behind glioma invasion. Neuro-Oncology. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 13-16, 2014, Miami, FL 16(Suppl_5):v120, 2014. e-Pub 2014.
- Jiang H, Lang F, Fan X, Gumin J, Bover L, Clise-Dwyer K, Toniatti C, Ruisard K, Conrad C, Vence L, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting co-stimulatory immune checkpoints proteins with oncolytic adenoviruses. Neuro-Oncology. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 13-16, 2014, Miami, FL 16(Suppl_5):v112, 2014. e-Pub 2014.
- Piya S, Jiang H, Klein SR, Yung WKA, Sawaya R, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses modulate autophagy in cancer cells via sumoylation of LC3. Proceedings of the 105st Annual Meeting of the American Association for Cancer Research (AACR); 2014 Apr 5-9; San Diego, CA, 2014. e-Pub 2014.
- Jiang H, Clise-Dwyer K, Fan X, GuminJ, Mukheef F, Bover L, Toniatti C, Ruisard K, Vence L, Yung WKA, Gomez-Manzano C, Fueyo J. Enhancement of anti-tumor immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. NIH/NCI Cancer Immunology and Immunotherapy: Delivering the Promise, October 9-10, 2014, Bethesda, MD, 2014. e-Pub 2014.
- Jiang H, Klein S, Piya S, Vence L, Yung WKA, Sawaya R, Heimberger A, Conrad C, Lang F, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD infection activates T-cell immune response against glioma cells. Neuro-Oncology (4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology, November 21-24, 2013, San Francisco, CA) 15(Suppl_3):iii63-iii64, 2013. e-Pub 2013.
- Piya S, White E, Klein S, Jiang H, Lang F, Yung WKA, Gomez-Manzano C, Fueyo J. Delta-24-RGD modulates autophagy in glioma cells by activation of the Beclin1/PI3KC complexes. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii70, 2011. e-Pub 2011.
- Jiang H, White E, Rios-Vicil CI, Yung WKA, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD induces cell lysis through autophagy and autophagy-triggered caspcase activation. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii116, 2011. e-Pub 2011.
- Piya S, White EJ, Jiang H, Klein S, McDonnell TJ, Yung WKA, Gomez-Manzano C, Fueyo J. The oncoprotein E1B19K is part of the Beclin 1 interactome in adenovirus-infected cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011. e-Pub 2011.
- Klein SR, Piya S, White EJ, Jiang H, Yung WKA, Gomez-Manzano C, Fueyo J. JNK1-phosphorylation of Bcl-2 is essential for adenoviral-induced autophagic cell death in glioma cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011. e-Pub 2011.
- Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White Em Xu J, McDonnell TJ, Shinojima N, Fueyo J. RB/E2F: gatekeepers of autophagy and apoptosis in glioma cells. 15th Annual Meeting of the Society of Neuro-Oncology (SNO), #CB-69, platform presentation, 2010. e-Pub 2010.
- Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White EJ, Xu J, McDonnell TJ, Shinojima N, Fueyo J. RB/E2F1 in the crossroads of autophagy and apoptosis. In: Proceedings of the 101st Annual Meeting of the Americal Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010. e-Pub 2010.
- Alonso M, Gomez-Manzano C, Vaillant B, Xu J, Liu D, Jiang H, White EJ, Colman H, Fueyo J. Salinomycin displays more potent anticancer effect against brain tumor stem cells than temozolomide. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010. e-Pub 2010.
- Liu D, Fueyo J, Martin V, Xu J, Cortes-Santiago N, Jiang H, White E, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma Cells with Tumor Microenvironment. 20th Annual Meeting of the European Neurological Society, 2010. e-Pub 2010.
- White EJ, Jiang H, Xu J, Gomez-Manzano C, Fueyo J. Involvement of autophagy in oncolysis: E1A is required but not sufficient. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;, 2009. e-Pub 2009.
- Jiang H, White E, Gumá S, Ji Y, Gomez-Manzano C, Conrad CA, Fueyo J. Enhanced oncolysis of glioma cells by Delta-24-RGD combining with 2-deoxyglucose through autophagic cell death. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;, 2009. e-Pub 2009.
- White E, Jiang H, Alonso M, Piao Y, Xu J, Conrad C, Yung WKA, Gomez-Manzano C, Fueyo J. Atg5 is required for adenovirus-induced autophagy in cancer cells. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
- Alonso M, Gomez-Manzano C, Jiang H, Martin V, Liu D, Xu J, Yung WKA, Gilbert M, Fueyo J. Role of the silencing of the MGMT promoter in the therapeutic synergy between Delta-24-RGD and temozolomide. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
- Jiang H, Xu X, Lang F, Colman H, Gomez-Manzano C, Bogler O, Latha K, Yung WKA, Fueyo J. Delta-24-RGD induces autophagy in brain tumor stem cells and prolongs survival in glioma-bearing mice. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008. e-Pub 2008.
- Jiang H, Gomez-Manzano C, Yokoyama T, Alonso MM, Kondo S, Xu J, Bekele BN, Colman H, Lang FF, Fueyo J. Oncolytic adenovirus Delta-24-RGD induces efficacious antiglioma activity in brain tumor stem cell models. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol, 2007. e-Pub 2007.
- Piao Y, Jiang H, Xu J, Alonso M, Lee OH, Conrad C, Yung WKA, Gomez-Manzano C, Fueyo J. Delta24-RIVER oncolytic adenovirus: targeting mutant EGFR glioma cells. 98th AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA, 2007. e-Pub 2007.
- Jiang H, Aoki H, Lee OH, Kondo S, Lang F, Yung WKA, Colman H, Gomez-Manzano C, Fueyo J. Cancer stem cells undergo autophagy after infection with oncolytic adenoviruses. 59th Annual Symposium on Cancer Research, 2006. e-Pub 2006.
- Alonso MM, Gomez-Manzano C, Lee OH, Jiang H, Piao Y, Alemany R, Lang F, Yung WKA, Fueyo J. Oncolytic strategies to target brain tumor stem cells and overcome MGMT-mediated temozolomide resistance. 59th Annual Symposium on Cancer Research, 2006. e-Pub 2006.
- Piao Y, Jiang H, Xu J, Ji YJ, Gomez-Manzano C, Conrad C, Fueyo J. Targeting mutant EGF receptor for glioma therapy using oncolytic adenoviruses. 10th Annual Trainee Recognition Day & Research Exposition, 2006. e-Pub 2006.
- Olson MV, Johnson DG, Aldape K, Fuller GN, Jiang H, Alonso MM, Yung WKA, Guha A, Gomez-Manzano C, Fueyo J. Transgenic mouse model provides the first direct evidence supporting the oncogenic role of E2F1 in brain. Proc Amer Assoc Cancer Res 47:643, 2006. e-Pub 2006.
- Jiang H, Olson MV, Xu J, Lee OH, Piao Y, Yung WKA, Fueyo J. Exportin 1-mediated nuclear export of adenovirus E1A protin: A novel target for generation of oncolytic viruses. Proc Amer Assoc Cancer Res 47:702-a, 2006. e-Pub 2006.
- Olson M, Jiang H, Medrano D, Gomez-Manzano C, Aldape K, Fueyo J. GFAP-E2F1 transgenic mouse provides the first evidence of an oncogenic role of E2F1 in brain tumor formation. Keystone Conferences: Cellular Senescence and Cell Death, Keystone, Colorado, 2005. e-Pub 2005.
- Olson M, Medrano D, Jiang H, Gomez-Manzano C, Alonso M, Aldape K, Price R, Yung WKA, Fueyo J. Developmental abnormalities and oncogenesis in the brain of a transgenic E2F1 mouse model. Neuro-Oncology 7:289, 2005. e-Pub 2005.
- Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Icovir-2, an old friend with a new face: E2F-1 mediated glioma selectivity for Delta24-RGD. Neuro-Oncology 7:377, 2005. e-Pub 2005.
- Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Oncolytic adenovirus Icovir-2 shows improved therapeutic index than D24-RGD for glioma. 96th annual meeting AACR, Anaheim, 2005. e-Pub 2005.
- Olson MV, Alonso M, Medrano D, Sheng X, Gomez-Manzano C, Jiang H, Yung WKA, Fueyo J. E2F1 transcriptionally activates PTEN. 96th annual meeting AACR, Anaheim, 2005. e-Pub 2005.
- Jiang H, Medrano D, Gomez-Manzano C, Lemoine M, Alemany R, Olson M, Alonso M, Conrad C, Yung WKA, Fueyo J. Downmodulation of E1A Protein Expression as a Novel Strategy to Design Cancer Selective Adenoviruses. 96th annual meeting AACR, Anaheim, 2005. e-Pub 2005.
- Jiang H, Alemany R, Gomez-Manzano C, Yung WK, Sawaya R, Lang FF, Fueyo J. Comparison of the Antiglioma Effect of E1A and E1B-55kD-Mutant Oncolytic Adenoviruses. [Oral Presentation] 2004 AANS/CNS Section on tumors Sixth Biennal Sattelite Symposium, San Francisco, 2004. e-Pub 2004.
- Medrano D, Jiang H, Johnson DG, Aldape K, Olson M, Gomez-Manzano C, Fueyo J. Transgenic overexpression of E2F1 in the brain in E2F4 null background results in severe hydrocephalus similar to E2F5 null mice. Special AACR Conference on Cell Cycle and Cancer: Pathways and Therapies, Fort Lauderdale, Florida, 2004. e-Pub 2004.
- Medrano D, Jiang H, Gomez-Manzano C, Olson M, Lemoine M, Yung WKA, Fueyo J. Replication-competent adenoviruses with impaired p300/CBP binding express low E1A protein levels: implications for oncolytic therapy. 8th Annual trainee recognition day and research exposition. UTMDACC, Houston, 2004. e-Pub 2004.
- Alonso MM, Gomez-Manzano C, Aldape K, Jiang H, Xu J, Kondo Y, Fueyo J. E2F1 upregulates telomerase: cell-cycle related telomerase activity in sarcoma cells. 95th. Annual Meeting, American Association for Cancer Research, Orlando, FL, 2004. e-Pub 2004.
- Jiang H, Gomez-Manzano C, Medrano D, Cass A, Alonso M, Alemany R, Yung WKA, Fueyo J. The level of E1A as a factor for tumor selectivity in oncolytic adenoviruses. 95th. Annual Meeting, American Association for Cancer Research, Orlando, FL, 2004. e-Pub 2004.
- Jiang H, Medrano D, Gomez-Manzano C, Courmier F, Yung WKA, Fueyo J. Replication competent adenoviruses with impaired p300/CBP binding express low E1A proteins levels: implication for oncolytic therapy. Neuro-Oncology 5:301-302, 2003. e-Pub 2003.
- Gomez-Manzano C, Jiang H, Stolarek R, Lang FF, Yung WK, Fuller GN, Fueyo J. U-87 MG Animal Model: predictability of growth kinetics and its use in oncolytic therapy for gliomas. Special AACR meeting, Orlando, FL, 2003. e-Pub 2003.
- Fueyo J, Gomez-Manzano C, Jiang H, Lemoine M, Stolarek R, Courmier F, Jasti S, Conrad C, Yung WKA. Oncolytic adenoviruses, CPT-11, and topoisomerase I: Mechanisms underlying chemosensitization. Neuro-Oncology 4:322, 2002. e-Pub 2002.
- Fueyo J, Gomez-Manzano C, Alemany R, Lemoine MG, Stolarek R, Jasti S, Courmier F, Jiang H, Lamfers M, Dirven C, Curiel DT, Yung WK. Oncolytic adenoviruses for gliomas therapy. 5th Congress of the European Association for Neuro-Oncology. Florence, Italy, 2002. e-Pub 2002.
- Gillard AG, Shin DH, Laspidea-Ustes V, Jiang H, Fan X, Yi Y, Hu J, Alonso M, Lang F, Fueyo J, Gomez-Manzano C. New insights on innate immune pathways sensing oncolytic adenoviruses. International Conference on Brain Tumor Research and Therapy 2023 (ICBTRT).
- Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Fan X, Yi Y, Ban K, Alemany R, Alonso M, Lang F, Gomez-Manzano C, Fueyo. Immune tolerance for viral antigens facilitates tumoral epitope spreading during oncolytic virotherapy. International Conference on Brain Tumor Research and Therapy 2023 (ICBTRT).
- Gillard A, Shin DH, Laspidea V, Singh S, Jiang H, Fan X, Yi Y, He J, Lopez-Rivas A, Lang FF, Fueyo J, Gomez-Manzano C. Exploring NONO as a potential innate immune sensor for oncolytic adenovirus in glioma treatment. CICON23 - 7th International Cancer Immunotherapy Conference: Translating Science into Survival.
- Shin DH, Jiang H, Gillard A, Fan X, Singh S, Lopez-Rivas A, He J, Parthasarathy A, Gumin J, Lang FF, Gomez-Manzano C, Fueyo J. Single Versus Multiple Injections of Oncolytic Adenoviruses in a Clinical Trial Suggests Strategies to Improve Cancer Virotherapy Through Immune-Evasion Strategies. CICON23 - 7th International Cancer Immunotherapy Conference: Translating Science into Survival.
- Shin DH, Lang FF, Jiang H, Gillard A, Nguyen T, Fan X, Singh S, Lopez-Rivas A, Parthasarathy A, Aleman D, Hampton LA, Ene C, Gumin J, Alonso MM, Fueyo J, Gomez-Manzano C. Chimeric hexon adenovirus evades neutralizing antibodies from patients treated with Delta-24-RGD oncolytic adenovirus. 15th Annual International Oncolytic Virotherapy Conference (IOVC) 2023.
- Shin DH, Gillard A, Jiang H, Lopez-Rivas A, Parthasarathy A, Fan X, Alonso M, He J, Nguyen D, Alvarez-Breckenridge C, Ene C, Lang F, Gomez-Manzano C, Fueyo J. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD. Cancer Neurosciences Program Scientific Retreat.
- Gillard A, Shin DH, Parthasarathy A, Lopez-Rivas A, Jiang H, He J, Frost M, Fan X, Xu BL, Alvarez-Breckenridge C, Lang F, Alonso M, Fueyo J, Gomez-Manzano C. NONO: A Novel Sensor of Adenovirus and Immune Regulator. Cancer Neurosciences Program Scientific Retreat.
- Morales-Rivera A, Fueyo J, Gomez-Manzano C, Gillard A, Lopez-Rivas A, Parthasarathy A, Jiang H, Singh S, Barrio IM, Akdemir K, Reuben A, Ene C, Hudson W, Lang F, Shin DH. Analysis of T Cell Receptors Reveals Biomarkers of Response in Virotherapy-Treated Gliomas. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back.
- Lopez-Rivas A, Shin DH, Parthasarathy A, Gillard A, Duran A, Gumin J, Alvarez-Breckenridge C, Lang F, Fueyo J, Gomez-Manzano C. JAK inhibition modulates polarization of macrophages to enhance viroimmunotherapy against gliomas. Nature Conferences - The Tumor Ecosystem: From Bench to Clinic and Back.
- Gupta S, Laspidea V, Fueyo J, Zaky W, Becher O, Nguyen TT, Shin DH, Jiang H, Sohoni S, Fan X, Yi Y, Gumin J, Lang FF, Gomez-Manzano C, Alonso MM. Armed oncolytic adenovirus as experimental therapy for pediatric malignant gliomas. The American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting 2022.
Book Chapters
- Gomez-Manzano C, Jiang H, Alonso MM, Yung WKA, Fueyo J. Gene Therapy. In: Neuro-Oncology. In series: Handbook of Clinical Neurology. 3rd ed. Elsevier, 331-8, 2012.
- Jiang H, Fueyo J. Gene therapy of brain tumors. In: Gene-based Therapies for Cancer. Springer Science + Business Media and Humana Press Inc, 17-32, 2010.
- Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. In: Methods in Enzymology: Autophagy in Disease and Clinical Applications. Part C. Academic Press, 273-86, 2009.
- Alonso MM, Gomez-Manzano C, Alemany R, Jiang H, McCormick F, Fueyo J. Conditionally replicative adenoviruses as antitumoral agents: Past, present and future. In: Cancer and Gene Therapy. Transworld Research Network, 41-54, 2007.
- Jiang H, McCormick F, Gomez-Manzano C, Curiel DT, Lang FF, Yung WKA, Fueyo J. Replicating viruses for brain tumor treatment. In: Gene Therapy for Neurological Disorders. Taylor and Francis Group, 293-326, 2006.
- Stolarek R, Fueyo J, Gomez-Manzano C, Jiang H, Yung WKA. Gene Therapy for Gliomas: Targeting the Cancer Genome. In: Genomic and Molecular Neuro-Oncology. In series: Molecular Oncology and Cancer Genomics. Jones and Bartlett Publishers, 281-302, 2003.
Books (edited and written)
- Jiang H, Li R. Reforming of Life. Hainan Publishing House, 1993.
Patient Reviews
CV information above last modified July 30, 2026